AGR2 and neoplasm: AGR2 immunostaining was unrelated to parameters of tumor aggressiveness in pancreatic, ovarian, and thyroidal cancer as well as papillary renal cell carcinoma although tumors with lower AGR2 expression often tended to exhibit more unfavorable tumor features.